Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 April 2021
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathwayStatus:In development | In consultationProgramme:Health technology evaluationConsultation end date: 25 September 2024Expected publication date: 19 December 2024
Lifileucel for previously treated unresectable or metastatic melanoma ID3863Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC